ADIL:NASDAQ, Adial Pharmaceuticals, Inc.
Why ADIL stock rose on October 28
Adial Pharmaceuticals, Inc. rose 36.1%
on Wednesday, October 28, 2026, on 83,085 shares.
The headline around the move:
ADIL stock overview
Adial Pharmaceuticals, Inc. (ADIL:NASDAQ) closed at $5.05 on October 28, 2026,
up 36.12% on the day.
The stock trades 42.3% below its 52-week high of $8.75
and 285.5% above its 52-week low of $1.31.
Adial Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
Key figures
- Price
- $5.05
- Day change
- +36.12%
- Volume
- 83,085
- Average volume
- 55,049
- Market cap
- 13M+
- 52-week range
- $1.31 – $8.75
- 50-day average
- $4.61
- 200-day average
- $3.13
Price action over the past year
In 252 trading sessions since November 19, 2025, ADIL closed higher on 100 days (40%).
Its best day was June 11, 2026 (+37.96%) and its worst was February 4, 2026 (-23.81%).
The stock moved 10% or more in a single session 24 times.
Recent signals
ADIL news
-
Nov 5, 2026:
Azora Therapeutics Appoints Board of Directors with Extensive Drug Development and Inflammatory Bowel Disease Expertise
-
Oct 28, 2026:
Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
-
Oct 26, 2026:
Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
-
Oct 16, 2026:
Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis
-
Sep 30, 2026:
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals Inc is a United States-based pharmaceutical company. The company develops prescription medications for addiction and related disorders.
Similar stocks
Find more stocks like ADIL with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.